AstraZeneca Plc has agreed to pay $75 million initially, and up to an additional $1.5 billion in option fees and milestone payments, for rights to up to three small molecule therapeutics for cancer. The partner is Scorpion Therapeutics Inc of Boston, US, which has an integrated platform for drug discovery drawing on chemical proteomics, structure-based drug design and machine learning.
